Disposition of 25000 shares by Hessekiel Jeffrey of Exelixis at 26.38 subject to Rule 16b-3

EXEL Stock  USD 35.59  0.87  2.39%   
About 76 percent of Exelixis' institutional investors are selling. The analysis of the overall investor sentiment regarding Exelixis suggests that many traders are terrified. Exelixis' investing sentiment shows overall attitude of investors towards Exelixis.
  
Filed transaction by Exelixis Officer: Evp & General Counsel. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Read at macroaxis.com
Disposition of 25000 common stock at 26.38 of Exelixis by Hessekiel Jeffrey on 23rd of September 2024. This event was filed by Exelixis with SEC on 2024-09-23. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Exelixis' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Exelixis' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Exelixis Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Exelixis can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Exelixis Historical Investor Sentiment

Investor biases related to Exelixis' public news can be used to forecast risks associated with an investment in Exelixis. The trend in average sentiment can be used to explain how an investor holding Exelixis can time the market purely based on public headlines and social activities around Exelixis. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Exelixis' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Exelixis and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Exelixis news discussions. The higher the estimate score, the more favorable the investor's outlook on Exelixis.

Exelixis Maximum Pain Price across 2024-12-20 Option Contracts

Exelixis' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Exelixis close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Exelixis' options.

Exelixis Fundamental Analysis

We analyze Exelixis' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Exelixis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Exelixis based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Book Value Per Share

Book Value Per Share Comparative Analysis

Exelixis is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

Exelixis Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Exelixis stock to make a market-neutral strategy. Peer analysis of Exelixis could also be used in its relative valuation, which is a method of valuing Exelixis by comparing valuation metrics with similar companies.

Peers

Exelixis Related Equities

PTCTPTC Therapeutics   18.66   
0%
100.0%
KODKodiak Sciences   11.39   
0%
61.0%
BTAIBioXcel Therapeutics   4.88   
0%
26.0%
TGTXTG Therapeutics   0.83   
0%
4.0%
HALOHalozyme Therapeutics   0.81   
0%
4.0%
ALNYAlnylam Pharmaceuticals   0.02   
1.0%
0%
KRYSKrystal Biotech   1.27   
6.0%
0%
BMRNBiomarin Pharmaceutical   1.50   
8.0%
0%
PDSBPDS Biotechnology   1.83   
9.0%
0%
VKTXViking Therapeutics   2.70   
14.0%
0%
MDGLMadrigal Pharmaceuticals   3.06   
16.0%
0%
SRPTSarepta Therapeutics   4.04   
21.0%
0%
XFORX4 Pharmaceuticals   5.13   
27.0%
0%
When determining whether Exelixis is a strong investment it is important to analyze Exelixis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Exelixis' future performance. For an informed investment choice regarding Exelixis Stock, refer to the following important reports:
Check out Exelixis Hype Analysis, Exelixis Correlation and Exelixis Performance.
For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. If investors know Exelixis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exelixis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
121.699
Earnings Share
1.55
Revenue Per Share
7.032
Quarterly Revenue Growth
0.143
Return On Assets
0.1281
The market value of Exelixis is measured differently than its book value, which is the value of Exelixis that is recorded on the company's balance sheet. Investors also form their own opinion of Exelixis' value that differs from its market value or its book value, called intrinsic value, which is Exelixis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exelixis' market value can be influenced by many factors that don't directly affect Exelixis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exelixis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Exelixis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exelixis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.